According to a recent LinkedIn post from RECEPTORAI, the company plans to attend the AACR Annual Meeting 2026 in San Diego from April 17 to 22. The post notes that CEO and founder Alan Nafiev, head of business development Askar Kuchumov, and an external partnership representative will be present for meetings.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights an interest in discussing oncology drug discovery challenges, including hit discovery and multiparameter optimization across small molecules, peptides, and protein–protein interaction programs. For investors, this suggests ongoing efforts to build partnerships and position the platform within oncology R&D workflows, which could influence future deal flow and collaboration-driven revenue.
The post also implies that RECEPTORAI is targeting engagement with pharmaceutical and biotech stakeholders attending AACR, one of the larger oncology research conferences. If successful, increased visibility and relationship-building at this event may enhance the company’s pipeline of prospective clients and collaborators, potentially supporting long-term commercialization prospects in cancer drug discovery technology.